Competitive Revision for CLARO: Collaboration Leading to Addiction Treatment and Recovery From Other Stresses

Summary

The purpose of this study is to develop and then test an enhanced version of the parent study's collaborative care intervention for co-occurring disorders (CC-COD) to reduce the risk of suicide and overdose among individuals with opioid use disorder (OUD) in combination with PTSD/depression. The parent study is CLARO, Collaboration Leading to Addiction Treatment and Recovery from Other Stresses (NCT04559893).

Conditions

• Opioid-use Disorder
• Addiction
• Depression
• Post Traumatic Stress Disorder
• Suicidal Ideation

Interventions

BEHAVIORAL

Collaborative care Plus

Collaborative care consists of a team of providers that includes a care coordinator, a primary care provider (PCP) and a behavioral health consultant (BHC), who provide evidence- and measurement-based care to a panel of patients using a clinical registry. In this model, the CC team also includes a behavioral health psychotherapist (BHP) who consults on a regular basis but does not deliver direct care. In the Collaborative Care Plus condition, the care coordinator involves family in care, teaches family about naloxone use, and provides Caring Contacts, a suicide prevention method, to patients.

Sponsors & Collaborators

• National Institute of Mental Health (NIMH)

  collaborator NIH

• University of New Mexico

  collaborator OTHER

• Boston Medical Center

  collaborator OTHER

• Hidalgo Medical Services

  collaborator UNKNOWN

• First Choice Community Healthcare

  collaborator UNKNOWN

• Stanford University

  collaborator OTHER

• University of Pittsburgh

  collaborator OTHER

• Olive View-UCLA Education & Research Institute

  collaborator OTHER

• Saint John's Cancer Institute

  collaborator OTHER

• RAND

  lead OTHER

Principal Investigators

• Katherine Watkins, MD · RAND

• Miriam Komaromy · Boston Medical Center

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-08-31

Primary Completion

2024-06-12

Completion

2024-06-12

Countries

• United States

Study Locations